Home > Publications Database > Fosmetpantotenate Randomized Controlled Trial in Pantothenate Kinase-Associated Neurodegeneration. > print

001     154280
005     20230915094032.0
024 7 _ |a pmc:PMC8246547
|2 pmc
024 7 _ |a 10.1002/mds.28392
|2 doi
024 7 _ |a pmid:33200489
|2 pmid
024 7 _ |a 0885-3185
|2 ISSN
024 7 _ |a 1531-8257
|2 ISSN
024 7 _ |a altmetric:94482955
|2 altmetric
037 _ _ |a DZNE-2021-00134
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Klopstock, Thomas
|0 P:(DE-2719)2810704
|b 0
|e First author
|u dzne
245 _ _ |a Fosmetpantotenate Randomized Controlled Trial in Pantothenate Kinase-Associated Neurodegeneration.
260 _ _ |a New York, NY
|c 2020
|b Wiley
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1653464494_4150
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a ISSN 1531-8257 not unique: **3 hits**.
520 _ _ |a Pantothenate kinase-associated neurodegeneration (PKAN) currently has no approved treatments.The Fosmetpantotenate Replacement Therapy pivotal trial examined whether treatment with fosmetpantotenate improves PKAN symptoms and stabilizes disease progression.This randomized, double-blind, placebo-controlled, multicenter study evaluated fosmetpantotenate, 300 mg oral dose three times daily, versus placebo over a 24-week double-blind period. Patients with pathogenic variants of PANK2, aged 6 to 65 years, with a score ≥6 on the PKAN-Activities of Daily Living (PKAN-ADL) scale were enrolled. Patients were randomized to active (fosmetpantotenate) or placebo treatment, stratified by weight and age. The primary efficacy endpoint was change from baseline at week 24 in PKAN-ADL.Between July 23, 2017, and December 18, 2018, 84 patients were randomized (fosmetpantotenate: n = 41; placebo: n = 43); all 84 patients were included in the analyses. Six patients in the placebo group discontinued treatment; two had worsening dystonia, two had poor compliance, and two died of PKAN-related complications (aspiration during feeding and disease progression with respiratory failure, respectively). Fosmetpantotenate and placebo group PKAN-ADL mean (standard deviation) scores were 28.2 (11.4) and 27.4 (11.5) at baseline, respectively, and were 26.9 (12.5) and 24.5 (11.8) at week 24, respectively. The difference in least square mean (95% confidence interval) at week 24 between fosmetpantotenate and placebo was -0.09 (-1.69 to 1.51; P = 0.9115). The overall incidence of treatment-emergent serious adverse events was similar in the fosmetpantotenate (8/41; 19.5%) and placebo (6/43; 14.0%) groups.Treatment with fosmetpantotenate was safe but did not improve function assessed by the PKAN-ADL in patients with PKAN. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
536 _ _ |a 344 - Clinical and Health Care Research (POF3-344)
|0 G:(DE-HGF)POF3-344
|c POF3-344
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a fosmetpantotenate
|2 Other
650 _ 7 |a pantothenate kinase-associated neurodegeneration
|2 Other
650 _ 7 |a randomized controlled trial
|2 Other
650 _ 7 |a treatment
|2 Other
650 _ 2 |a Activities of Daily Living
|2 MeSH
650 _ 2 |a Double-Blind Method
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Pantothenate Kinase-Associated Neurodegeneration: drug therapy
|2 MeSH
650 _ 2 |a Pantothenate Kinase-Associated Neurodegeneration: genetics
|2 MeSH
650 _ 2 |a Pantothenic Acid: analogs & derivatives
|2 MeSH
700 1 _ |a Videnovic, Aleksandar
|b 1
700 1 _ |a Bischoff, Almut Turid
|b 2
700 1 _ |a Bonnet, Cecilia
|b 3
700 1 _ |a Cif, Laura
|0 0000-0003-4920-4234
|b 4
700 1 _ |a Comella, Cynthia
|b 5
700 1 _ |a Correa-Vela, Marta
|0 0000-0002-6255-5197
|b 6
700 1 _ |a Escolar, Maria L
|b 7
700 1 _ |a Fraser, Jamie L
|b 8
700 1 _ |a Gonzalez, Victoria
|b 9
700 1 _ |a Hermanowicz, Neal
|b 10
700 1 _ |a Jech, Robert
|0 0000-0002-9732-8947
|b 11
700 1 _ |a Jinnah, Hyder A
|b 12
700 1 _ |a Kmiec, Tomasz
|b 13
700 1 _ |a Lang, Anthony
|b 14
700 1 _ |a Martí, Maria J
|b 15
700 1 _ |a Mercimek-Andrews, Saadet
|b 16
700 1 _ |a Monduy, Migvis
|b 17
700 1 _ |a Nimmo, Graeme A M
|b 18
700 1 _ |a Perez-Dueñas, Belen
|b 19
700 1 _ |a Pfeiffer, Helle Cecilie Viekilde
|b 20
700 1 _ |a Planellas, Lluis
|b 21
700 1 _ |a Roze, Emmanuel
|b 22
700 1 _ |a Thakur, Nivedita
|b 23
700 1 _ |a Tochen, Laura
|b 24
700 1 _ |a Vanegas-Arroyave, Nora
|b 25
700 1 _ |a Zorzi, Giovanna
|b 26
700 1 _ |a Burns, Colleen
|b 27
700 1 _ |a Greblikas, Feriandas
|b 28
773 _ _ |a 10.1002/mds.28392
|g p. mds.28392
|0 PERI:(DE-600)2041249-6
|n 6
|p 1342 - 1352
|t Movement disorders
|v 36
|y 2020
|x 1531-8257
856 4 _ |u https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mds.28392
856 4 _ |u https://pub.dzne.de/record/154280/files/18599.pdf
|y OpenAccess
856 4 _ |u https://pub.dzne.de/record/154280/files/18599.pdf?subformat=pdfa
|x pdfa
|y OpenAccess
909 C O |o oai:pub.dzne.de:154280
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)2810704
913 1 _ |a DE-HGF
|b Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-344
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
913 2 _ |a DE-HGF
|b Programmungebundene Forschung
|l ohne Programm
|1 G:(DE-HGF)POF4-890
|0 G:(DE-HGF)POF4-899
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-800
|4 G:(DE-HGF)POF
|v ohne Topic
|x 0
914 1 _ |y 2020
915 _ _ |a Creative Commons Attribution-NonCommercial CC BY-NC 4.0
|0 LIC:(DE-HGF)CCBYNC4
|2 HGFVOC
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2021-01-30
|w ger
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-30
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-30
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2022-11-11
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b MOVEMENT DISORD : 2021
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-11
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2022-11-11
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b MOVEMENT DISORD : 2021
|d 2022-11-11
920 1 _ |0 I:(DE-2719)1111016
|k Clinical Dementia Research München
|l Clinical Dementia Research München
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1111016
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21